Further, we aimed to investigate the predictive significance of sPD-1 and sPD-L1 in comparison with a control cohort of EGFR-mutated NSCLC patients, since expected sensitivity to immunotherapy is minimal in this subset of NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.